Concluded · 2026 Conference
7th Saudi Lymphoma/Myeloma and 10th Hematopathology Overview
View poster
Concluded · 2026 Conference
View poster
The objectives of this conference are as follows
This educational program is intended for Hematologists, Hemato-Pathologists, Medical Oncologists, Radiation Oncologists, Nuclear Medicine Specialists, Fellows and Residents in Training, Lab Scientists, Lab Technicians and technologists, and other healthcare providers who are involved in and/or interested in hematological disorders and SCT. State-of-the-art lectures, evidence-based hematology sessions, and satellite symposia covering the latest technological developments will be the main features of the program.
Shaji Kumar is a distinguished physician-scientist and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota. He is internationally renowned for his clinical and translational research in multiple myeloma, amyloidosis, and other plasma cell disorders. Born in India, Dr. Kumar earned his medical degree from the All-India Institute of Medical Sciences (AIIMS).
He subsequently relocated to the United States, completing his residency and fellowship training in internal medicine, hematology, and medical oncology at the Mayo Clinic and the Dana-Farber Cancer Institute. Dr. Kumar is a consultant and professor of medicine at the Mayo College of Medicine and serves as the Medical Director for the Cancer Center Clinical Trials Office at the Mayo Clinic. He is heavily involved in the development of new therapeutic agents and chairs and acts as principal investigator for multiple phase 1, 2, and 3 clinical trials for plasma cell malignancies.
His laboratory work focuses heavily on the tumor microenvironment and the molecular mechanisms behind diseases like multiple myeloma. A prolific researcher, he has published over 500 peer-reviewed articles and abstracts. He holds leadership roles in professional societies, serving on the boards of multiple medical journals and the International Myeloma Society.
In 2024, he was recognized with the Robert A. Kyle Lifetime Achievement Award by the International Myeloma Foundation.
Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford, UK.
He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 185 peer-review articles on lymphoma and CLL. He is the low grade lymphoma clinical trial research group chair in the UK.
He is a core member several lymphoma studies groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes. He is an Associate Editor at the British Journal of Haematology. He is the lead author for the new ESMO Lymphoma guidelines.
Dr. Ann S. LaCasce has been a member of the Lymphoma Program at Dana-Farber since 2002. She is the Program Director of the Dana-Farber/Mass General Brigham Fellowship in hematology/oncology and is the co-chair of the Alliance lymphoma Committee. She is an Associate Professor of Medicine at Harvard Medical School.
María-Victoria Mateos, MD, PhD is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.
She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering MM patients that have profoundly influenced current options for treating these patient populations. She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH.
She has published over 140 papers in peer-reviewed international journals, some of which have become key references in the Multiple Myeloma field. She is Associate Editor of myeloma in Annals of Haematology since 2011 and has acted as a reviewer for top journals such as NEJM, Lancet and Lancet Oncology. Among her invited presentations, she has recently contributed to the educational sessions of EHA 2012, ASH 2013 and ASCO 2015.
She has served on the EHA’s Scientific Program Committee and Advisory Board since 2014 until 2016, and on the ASH Scientific Committee on plasma cell diseases in 2015.
She is a Councillor on the EHA Board since 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee.
Dr. Fatima Aldarweesh is an Associate Professor of Pathology at the University of Chicago, where she serves as Medical Director of the Transfusion Medicine and Hemostasis Section and Program Director of the Transfusion Medicine Fellowship. She is board-certified in Clinical Pathology and Blood Banking/Transfusion Medicine by the American Board of Pathology. She earned her MD with honors from King Faisal University in Saudi Arabia, completed her Clinical Pathology residency at Brown University, USA, and her Transfusion Medicine fellowship at the University of Wisconsin, Madison, USA.
Dr. Aldarweesh's clinical and administrative work spans transfusion medicine, therapeutic apheresis, and hemostasis, with a particular focus on blood inventory management, donor requalification, and out-of-hospital transfusion programs.
Dr. Ahmed Al Bahrani, Consultant hematopathology, transfusion medicine and cellular therapy. He is the chairman of blood bank, and cellular therapy processing laboratory and head of Apheresis unit at king Fahad specialist hospital Dammam. Chairman of blood utilization review committee, board member of Saudi society of blood disorder, CBAHI surveyor and visit team leader.
Also, Dr. Al Bahrani is the program director of Histopathology residency program.
Dr. Reem Alrabeh is a Consultant in Hematopathology and has been the Section Head of the Hematology, Coagulation, and Flow Cytometry Lab at King Fahad Specialist Hospital - Dammam since 2022.
Dr. Maher M. Aljohani, MD, MSc is a Consultant and Assistant Professor of Hematopathology, Chairman of the Department of Pathology and Laboratory Medicine, Prince Mohammad Bin Abdul Aziz Hospital (PMBAH) of National Guard Health Affairs, Madinah, Saudi Arabia. He is also a Consultant Hematopathology at King Abdulaziz Medical City, Ministry of National Guard, and NGHA, KAMC - Jeddah. Saudi Arabia.
Hematopathology Consultant/Coagulation and Hemostasis, King Fahad Specialist Hospital, Dammam, Saudi Arabia
Dr. Rahaf Altahan is a Consultant Hematopathologist at King Fahad Medical City and the Program Director of the King Saud University Board in Hematopathology and Transfusion Medicine.
Dr. Altahan holds a Board degree in Hematopathology and Transfusion Medicine from King Saud University and a Clinical Fellowship in Advanced Laboratory Coagulation and Hemostasis from McMaster University, Canada.
Dr. Ammar Hasan Alsughayir is a distinguished leader in transfusion medicine with over 20 years of experience steering clinical laboratories and blood banks to meet the highest international standards. As Chairman of the Transfusion Medicine Service Department at King Fahad Medical City, he has driven transformative initiatives, including expanding blood bank services, establishing remote blood banks, and achieving prestigious accreditations such as CAP, CBAHI, and AABB. A certified clinical pathologist and hematologist, Dr. Alsughayir holds an MBBS from King Saud University College of Medicine, a Jordanian Board of Hematology, and completed fellowships in Neoplastic Hematopathology and Transfusion Medicine/Bone Marrow Transplant at the University of Ottawa, Canada.
He is also a certified Hemapheresis Practitioner by the American Society of Pathologists, a College of American Pathologist Certified Inspector, and a certified assessor for the Saudi Commission for Health Specialties. As a medical consultant for stem cell processing and bone marrow transplantation, he provides specialized clinical expertise. His academic contributions include serving as Assistant Professor at King Saud University and Alfaisal University, directing the Transfusion Medicine Residency Diploma Program, and leading quality improvement projects that earned national recognition, such as the 2020 MOH Ehsan Award.
A prolific researcher and regular presenter at global conferences,
Consultant Hematopathology, King Fahad Specialist Hospital – Dammam (KFSH-Dammam) and Professor of Hematopathology, National Cancer Institute, Cairo University
Dr. Omar Zeid Abduljalil, MBBS, SF-AH, SB-Med, MHQS is a Consultant in Adult Hematology and Bone Marrow Transplantation at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where he also serves as Head of Quality and Patient Safety in the department. He is a member of the Hematology Examination Committee for the Saudi Commission for Health Specialties and holds a Master’s degree in Healthcare Quality and Safety from Harvard Medical School. Dr. Abduljalil completed advanced clinical fellowships in hematology and bone marrow transplantation at the University of Toronto.
His work is distinguished by a strong focus on multiple myeloma, stem cell transplantation, and healthcare quality
Assistant Professor and Consultant Hematologist with a special interest in malignant hematology, particularly lymphoproliferative disorders. Published in high-impact factor journals and holds a master’s degree in health science from the University of British Columbia.
Assistant Professor of Hematology/Oncology, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA, and a Consultant, Div. of Adult Hematology and Stem Cell Transplantation, Department of Oncology, King Abdulaziz Medical City - Riyadh, since August 9, 2008.
Dr. Mohammad Awaji is the principal director of the Histocompatibility & Immunogenetics Laboratory at King Fahad Specialist Hospital-Dammam in Saudi Arabia. A highly accomplished clinical scientist and laboratory director, he oversees high-complexity testing for organ and stem cell transplantation, maintains international accreditations, and provides expert consultation in transplant immunology and Immunogenetics. With a PhD from the University of Nebraska Medical Center and extensive research experience in cancer and transplant immunobiology, Dr. Awaji has authored numerous publications, leads national committees, and actively advances histocompatibility practices in Saudi Arabia through education, policy, and innovation.
Dr. Mohammed Al Sharif is a Consultant Hematopathologist with subspecialty in coagulation and hemostasis at King Abdullah bin Abdulaziz University Hospital (KAAUH). He earned his MBBS degree from King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) and completed a clinical fellowship in advanced laboratory coagulation and hemostasis at McMaster University.
Regular Speaker at the department of Training and Continuous Education in MCHD
Blood Bank management and Improvement project planning
Multiple national conferences Presentation
Laboratory CAP,CBAHI Accreditation Team Leader
Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a B.S. in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University. Seeking an
internal medicine residency program with particular strength in oncology, Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship.
Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for
patients with CLL and Richter’s Syndrome, which is the focus of his research.
Dr Khalil Al Farsi is a senior consultant hematologist at Sultan Qaboos University Hospital and Head of the Department of Hematology. His clinical and academic interests include multiple myeloma, lymphoma, autologous stem-cell transplantation, CAR-T cell therapy, clinical research, and postgraduate hematology education.
Dr. Majed Alahmadi is a Consultant in Adult Hematology and BMT at Princess Noorah Oncology Center, KAMC in Jeddah. Board-certified in Internal Medicine and Hematology in Saudi Arabia, Canada, and the US, he completed advanced fellowship training in lymphoma, myeloma, and BMT at Princess Margaret Cancer Centre.
Dr. Mohammed Ibrahim M Aldarweesh is a Consultant in Adult Hematology, Lymphoma, Myeloma, and Stem Cell Transplantation at King Fahad Specialist Hospital–Dammam. He completed advanced fellowships at Princess Margaret Cancer Center in Toronto and holds Saudi and Jordanian Board certifications in Hematology.
Prof. Lu Jin is a Chief Physician, Professor, and Doctoral Supervisor at Peking University People's Hospital / Peking University Institute of Hematology. She specializes in multiple myeloma, primary systemic amyloidosis, lymphoma, and cellular immunotherapy. She has published over 100 papers and served as principal investigator for more than 30 domestic and international multicenter clinical trials.
She currently holds key positions including President of the Beijing Medical Association Hematology Branch, Vice Chair of the CSCO Myeloma Expert Committee, and Member of the International Myeloma Working Group (IMWG).
Stephen M. Ansell, MD, PhD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota. Dr. Ansell currently serves as chair of the Division of Hematology and the Enterprise Deputy Director of the Mayo Clinic Cancer Center. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine and Science.
Dr. Ansell earned his MB, ChB, and PhD degrees at University of Pretoria in Pretoria, South Africa, where he also completed an internship in internal medicine and surgery, a residency in internal medicine, and a fellowship in medical oncology. Dr. Ansell continued his education at University of the Witwatersrand in Johannesburg where he was a registrar in internal medicine. He then came to the United States and completed a residency in internal medicine and then a fellowship in hematology/oncology at Mayo Clinic.
Dr. Ansell’s research focuses on investigating the phenotype and activity of intratumoral T-cells and developing strategies to modulate the immune function in lymphomas.
Tycel Phillips, MD is an Associate Professor of Medicine at the City of Hope National Medical Center in Duarte, California. His clinical research experience has allowed him to grow his expertise in the field of lymphoma. Over the last several years, he has led numerous clinical studies in the role of site and national primary investigator.
With his role as an investigator, he has become well versed in the mechanism of action, side effects and best applications for non-cytotoxic drugs in the treatment of lymphoma. While versed in all subtypes of lymphoma, he has a particular interest and clinical focus in
mantle cell lymphoma (MCL). He has participated in the design and implementation of numerous investigator initiated clinical trials focused on patients with both untreated and relapsed/refractory MCL. This is in addition to coordinating several national industry sponsored studies with an emphasis on this patient population. He has worked with and
helped with the development of several novel agents, including monoclonal antibodies, bispecific T cell engagers, CAR-T, drug antibody conjugates, pathway inhibitors and BH3 mimetics. He has also been able to evaluate the effectiveness or lack of these drugs at various stages of treatment. He is currently a member of the LRF MCL executive committee, and SWOG lymphoma committee.
His work has allowed him to gain a deeper understanding of the mechanisms of response and resistance in mantle cell lymphoma which he has then translated into his research program.
Dr Mariam AlGhazal medical director and head of hematopathology and flowcytometry in Dammam regional laboratory with over 20 years experience in hematopathology and flowcytometry ,main interest is dignostic hematological malignancy and coagulation
Dr. Solaf Sami Kanfar is the Chairperson of the Adult Hematology & SCT Department at King Fahad Specialist Hospital in Dammam and an Honorary Assistant Professor at Imam Abdulrahman Bin Faisal University. Dual board-certified in internal medicine and hematology, she completed advanced leukemia and stem cell transplantation fellowships at the Princess Margaret Cancer Center, University of Toronto
Dr. Wael Alanazi, Consultant in Adult Hematology and Bone Marrow Transplantation at King Fahad Specialist Hospital-Dammam. I hold an MD from Arabian Gulf University in Bahrain and completed my Internal Medicine Residency at National Guard Health Affairs in Al-Ahsa, Saudi Arabia. I’m board-certified in Internal Medicine and Adult Hematology in Saudi Arabia and completed a Clinical Fellowship in Hematology/Bone Marrow Transplantation at the University of Toronto, Canada.
My main interest is managing complex hematologic disorders, including leukemias, myeloproliferative disorders, platelet and bleeding disorders.
Dr. Abdulkareem AlGarni is a Consultant Hematologist at King Abdulaziz Hospital, MNGHA, and an Assistant Professor at King Saud bin Abdulaziz University for Health Sciences. His clinical and academic interests focus on malignant hematology, with a particular interest in advancing patient care through research and innovation, alongside a strong commitment to medical education.
Dr. Ghazi Saud Alotaibi is the Director of the King Saud University Oncology Center, Assistant Professor of Medicine, and Founder and Chair of the Saudi Myeloma Working Group. American and Canadian board-certified, he completed specialized fellowship training in plasma cell dyscrasias at the Mayo Clinic.
Dr. Khalid Aldosari is a Consultant Hematologist at King Abdulaziz Medical City, Ministry of National Guard Health Affairs in Riyadh. As a member of the Lymphoma Group, his primary clinical and research interests center on advancing lymphoma management.
Dr. Aamer Bugnah is a Consultant in Adult Hematology and Stem Cell Transplantation at King Saud Medical City, Riyadh. Saudi Fellowship–certified, he completed his fellowship training at King Faisal Specialist Hospital. He currently serves as Head of the Hematology-Oncology Department and Cluster Lead for Oncology Services.
Dr. Fatimah Abdulwahid Al Ghanim is the Head of the Blood Bank at Qatif Central Hospital and a Consultant in Transfusion Medicine. German Board-certified (Fachärztin), she completed her residency training at Charité University Hospital in Berlin and leads local blood utilization and hospital accreditation initiatives.
Dr. Naif Bin Muhannaa is an Acting Specialty Consultant in Transfusion Medicine at King Fahad Medical City in Riyadh. He completed his hematopathology fellowship at King Saud University and an advanced transfusion medicine clinical fellowship at Western University and Canadian Blood Services.
Prof. Mubarak Al Mansour is the Chairman of the Oncology Department and Consultant, Adult Medical Oncology at the Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs - Jeddah, Saudi Arabia. He has held this leadership position since February 2022, overseeing the department's clinical and administrative operations and ensuring the delivery of high-quality, efficient and coordinated oncology services.
He is also a Consultant in Adult Medical Oncology at the King's College Hospital London, Jeddah.
Thank you to everyone who took part in 7th Saudi Lymphoma/Myeloma and 10th Hematopathology Overview.
This event has already taken place. View the highlights in our gallery, or contact us about upcoming events.
12RM0001234 — with no spaces or dashes.
CME hours cannot be credited to your profile without a correct number.By registering for the 7th Saudi Lymphoma/Myeloma and 10th Hematopathology Overview, you agree to the following terms and conditions:
For any questions or concerns, please contact:
By clicking "I Accept", you acknowledge that you have read, understood, and agree to these terms and conditions.
This website uses only the cookies it needs to work — none for advertising or tracking. YouTube sets its own only when you play a video. Privacy Policy